A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type
Abstract Patients with stage IE/IIE natural killer T (NK/T) cell lymphomas have discrepant survival outcome. This study aims to establish a prognostic model based on the pretreatment platelet lymphocyte ratio (PLR) specifically for localized extranodal NK/T cell lymphoma to guide the therapy. We retrospectively analyzed the data of 252 patients with early-stage upper aerodigestive tract NK/T cell lymphoma. The 5-year overall survival rate in 252 patients was 67.1 %. Prognostic factors for survival were female (P = 0.025; relative risk, 0.51; 95 % CI 0.28–0.92), older age (P = 0.000; relative risk, 3.34; 95 % CI 1.94–5.75), stage II(P = 0.020; relative risk, 1.79; 95 % CI 1.10–2.91), lactate dehydrogenase (LDH) level (P = 0.009; relative risk, 2.00; 95 % CI 1.19–3.35), and PLR (P = 0.020; relative risk, 1.77; 95 % CI 1.10–2.87). Based on these five parameters, we identified three different risk groups: group 1(106 cases, 43.4 %), no or one adverse factor; group 2(85 cases, 34.8 %), two factors; group 3(53 cases, 21.7 %), three to five factors. Five-year overall survival was 83.3 % for group 1, 62.2 % for group 2, and 43.1 % for group 3 (P = 0.000). Compared with International Prognostic Index and Korean Prognostic Index, the new model has a better prognostic discrimination for the patients of stage IE/IIE upper aerodigestive tract NK/T cell lymphoma. The PLR-based prognosis model is useful to stratify patients with localized extranodal NK/T cell lymphoma into different risk groups and guide the treatment modalities selection..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2014 |
---|---|
Erschienen: |
2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
---|---|
Enthalten in: |
Medical oncology - 31(2014), 12 vom: 07. Nov. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Ke-feng [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
International Prognostic Index |
Anmerkungen: |
© Springer Science+Business Media New York 2014 |
---|
doi: |
10.1007/s12032-014-0318-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2102618943 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2102618943 | ||
003 | DE-627 | ||
005 | 20230402060040.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230402s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12032-014-0318-8 |2 doi | |
035 | |a (DE-627)OLC2102618943 | ||
035 | |a (DE-He213)s12032-014-0318-8-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.81$jOnkologie |2 bkl | ||
100 | 1 | |a Wang, Ke-feng |e verfasserin |4 aut | |
245 | 1 | 0 | |a A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer Science+Business Media New York 2014 | ||
520 | |a Abstract Patients with stage IE/IIE natural killer T (NK/T) cell lymphomas have discrepant survival outcome. This study aims to establish a prognostic model based on the pretreatment platelet lymphocyte ratio (PLR) specifically for localized extranodal NK/T cell lymphoma to guide the therapy. We retrospectively analyzed the data of 252 patients with early-stage upper aerodigestive tract NK/T cell lymphoma. The 5-year overall survival rate in 252 patients was 67.1 %. Prognostic factors for survival were female (P = 0.025; relative risk, 0.51; 95 % CI 0.28–0.92), older age (P = 0.000; relative risk, 3.34; 95 % CI 1.94–5.75), stage II(P = 0.020; relative risk, 1.79; 95 % CI 1.10–2.91), lactate dehydrogenase (LDH) level (P = 0.009; relative risk, 2.00; 95 % CI 1.19–3.35), and PLR (P = 0.020; relative risk, 1.77; 95 % CI 1.10–2.87). Based on these five parameters, we identified three different risk groups: group 1(106 cases, 43.4 %), no or one adverse factor; group 2(85 cases, 34.8 %), two factors; group 3(53 cases, 21.7 %), three to five factors. Five-year overall survival was 83.3 % for group 1, 62.2 % for group 2, and 43.1 % for group 3 (P = 0.000). Compared with International Prognostic Index and Korean Prognostic Index, the new model has a better prognostic discrimination for the patients of stage IE/IIE upper aerodigestive tract NK/T cell lymphoma. The PLR-based prognosis model is useful to stratify patients with localized extranodal NK/T cell lymphoma into different risk groups and guide the treatment modalities selection. | ||
650 | 4 | |a Natural killer/T cell lymphoma | |
650 | 4 | |a Upper aerodigestive tract | |
650 | 4 | |a Platelet lymphocyte ratio | |
650 | 4 | |a Prognostic model | |
650 | 4 | |a International Prognostic Index | |
650 | 4 | |a Korean Prognostic Index | |
700 | 1 | |a Chang, Bo-yang |4 aut | |
700 | 1 | |a Chen, Xiao-qin |4 aut | |
700 | 1 | |a Liu, Pan-pan |4 aut | |
700 | 1 | |a Wuxiao, Zhi-jun |4 aut | |
700 | 1 | |a Wang, Zhi-hui |4 aut | |
700 | 1 | |a Li, Su |4 aut | |
700 | 1 | |a Jiang, Wen-qi |4 aut | |
700 | 1 | |a Xia, Zhong-jun |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medical oncology |d Springer US, 1984 |g 31(2014), 12 vom: 07. Nov. |h Online-Ressource |w (DE-627)320468240 |w (DE-600)2008172-8 |w (DE-576)288571770 |x 1559-131X |7 nnns |
773 | 1 | 8 | |g volume:31 |g year:2014 |g number:12 |g day:07 |g month:11 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12032-014-0318-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2136 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2474 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4328 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 44.81$jOnkologie |q VZ |0 106409433 |0 (DE-625)106409433 |
951 | |a AR | ||
952 | |d 31 |j 2014 |e 12 |b 07 |c 11 |